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Accumulating evidence suggest that infection with Chlamydia pneumoniae is associated
with atherosclerosis, but the mechanisms involved remain unclear. Inflammation is important
in the initial phase of atherogenesis, and cytokines are important in the initiation and pro-
gression of inflammation. The aim of this study was to assess the capacity of acellular com-
ponents of C. pneumoniae to stimulate the production of pro-inflammatory cytokines and
chemokines. Peripheral blood mononuclear cells were stimulated in vitro with sonicated
C. pneumoniae. Significant amounts of TNF- § , IL-1, IL-6, IL-8, monocyte chemoattractant
protein-1 (MCP-1) and macrophage inflammatory protein-1 § (MIP-1 § ) were produced. Inhi-
bition of endotoxin using polymyxin B revealed that chlamydial endotoxin plays a minor role
in the cytokine induction. Neutralization of TNF by TNF-binding protein and blockade of IL-1
receptors by IL-1 receptor antagonist revealed that TNF, IL-1 and IL-6 production was inde-
pendent from each other, whereas IL-8 synthesis was strongly dependent on endogenous
TNF and IL-1. In contrast, synthesis of MCP-1 and MIP-1 § was dependent on endogenous
TNF, but not IL-1. In conclusion, acellular components of C. pneumoniae are a potent stimu-
lus for cytokine production, and this mechanism may have an important role in the inflamma-
tory aspects of atherogenesis.
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1 Introduction
The importance of infectious episodes for the process of
atherogenesis has been proposed for several decades,
but evidence for this concept has only recently been
reported [1, 2]. Chlamydia pneumoniae is a gram-
negative obligate intracellular pathogen which causes
respiratory tract infections [3, 4]. Initial studies were
reported 10 years ago which showed that patients with
acute myocardial infarction and established coronary
artery disease had significantly higher titers of antibodies
against Chlamydia compared to healthy controls [5],
whereas patients with elevated IgA titers against
C. pneumoniae had a twofold increased risk to suffer
from a major cardiac event in the following 6 months [6].
Since then, several studies have generally confirmed this
connection between serological evidence of C. pneumo-
niae infection and coronary heart disease (for review see
[7]). In addition, C. pneumoniae has been detected in
atheromatous lesions from patients [8–10]. These sero-
logical and pathological studies have been joined by two
small trials showing that treatment with macrolides, anti-
biotics with anti-chlamydial potency, results in dimin-
ished chance of major cardiac events in patients with
unstable angina [11] or after a prior mycocardial infarc-
tion [12]. Recently, the interim report of the ACADEMIC
study has described that treatment of coronary artery
disease patients with azithromycin improved markers of
Eur. J. Immunol. 2000. 30: 541–549 Stimulation of cytokines by Chlamydia pneumoniae sonicates 541
Fig. 1. Stimulation of cytokine production by C. pneumo-
niae. Human PBMC were stimulated for 24 h with condi-
tioned medium (open bars) or sonicated C. pneumoniae
(hatched bars). (A) TNF, IL-1 g and IL-6, (B) IL-8, MCP-1 and
MIP-1 § ; (n = 8 donors. *p X 0.01 when compared with stim-
ulation by conditioned medium.
inflammation, but did not influence clinical events after
the initial 6 months of follow-up [13]. Larger clinical stud-
ies with a longer follow-up are under way to confirm
or disprove these initial reports. The possibility that
C. pneumoniae has a role in the pathogenesis of athero-
sclerosis has been strengthened by recent animal stud-
ies in which infection with C. pneumoniae induced or
accelerated atherosclerosis [14, 15].
The pathophysiological mechanisms by which C. pneu-
moniae may contribute to the development of athero-
sclerosis are not yet fully understood. In vitro studies
have shown that C. pneumoniae can infect monocytes/
macrophages and smooth muscle cells [16], and can
induce macrophage foam cell formation [17, 18]. The
multiplication of Chlamydia inside monocytes or macro-
phages triggers the production of pro-inflammatory
cytokines such as TNF- § , IL-1 and IL-6 [19, 20], pro-
inflammatory cytokines found in atherosclerotic plaques
which play an important role in the inflammatory pro-
cesses involved in atherogenesis [21]. In addition, in-
fection of endothelial cells by C. pneumoniae induces
expression of adhesion molecules such as endothelial-
leukocyte adhesion molecule 1, intercellular adhesion
molecule (ICAM)-1, and vascular cell adhesion molecule
[22], and stimulates transendothelial migration of neutro-
phils and monocytes [23].
However, several important questions remain unan-
swered to date. It is not known whether infection of
human cells with live bacteria is needed for cytokine
stimulation, or whether stimulation can by induced by
chlamydial antigens, LPS, major outer membrane protein
(MOMP) or heat shock proteins. In this respect, it has
been suggested that chlamydial heat shock protein 60 is
able to induce production of TNF by murine macro-
phages [24] and activate human vascular endothelium,
smooth muscle cells and macrophages [25]. In addition,
no information is available regarding the capacity of
C. pneumoniae to stimulate human mononuclear cells for
the production of chemokines. The latter are essential for
monocyte and lymphocyte extravasation into the arterial
wall, a crucial event in the early phase of atherogenesis.
The precise mechanism of cytokine stimulation by
C. pneumoniae is also undefined, and the proximal regu-
lators of Chlamydia-induced mononuclear cell activation
are unknown.
The aims of the present study were to investigate several
key aspects of cytokine stimulation by C. pneumoniae. Is
infection with live C. pneumoniae required for stimulation
of cytokine production by PBMC, or are molecular com-
ponents from dead C. pneumoniae also cell activators?
Is C. pneumoniae able to induce production of chemo-
kines such as IL-8, monocyte chemoattractant protein
(MCP)-1 and macrophage inflammatory protein (MIP)-1 §
from human mononuclear cells, and which cytokines act
as regulators of the cytokine network activated by
C. pneumoniae? Is the LPS component of C. pneumo-
niae involved in the cytokine stimulation? Information
regarding the stimulatory pathways induced by C. pneu-
moniae may have important consequences for under-
standing the mechanisms through which this microor-
ganism promotes early atherosclerosis, and for finding
effective strategies in counteracting its deleterious
effects.
2 Results
2.1 Stimulation of pro-inflammatory cytokines
and chemokines by sonicated C. pneumoniae
Stimulation of human PBMC for 24 h with sonicated
C. pneumoniae from a culture containing 104 inclusion-
forming units (IFU)/ml resulted in significant stimulation
of the production of TNF, IL-1 g and IL-6, compared with
the stimulation with the conditioned medium from unin-
fected Hep2 cells on which the microorganism was
grown (Fig. 1 A). Whereas TNF and IL-1 g were signifi-
cantly increased over control (five- and twofold, respec-
tively), IL-6 production was increased 40-fold. Since IL-6
is a growth factor for vascular smooth muscle cells, the
particular induction of IL-6 in these cultures suggests
that Chlamydia infection in vascular tissue may acceler-
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Table 1. IFN- + production of human PBMC or lymphocytes from 4 healthy volunteers after stimulation with sonicated C. pneu-
moniae
PBMC Lymphocytesa)
IFN- + (pg/ml)b) Conditioned medium C. pneumoniae Conditioned medium C. pneumoniae
Donor 1 40 215 (5)c) 35 210 (6)
Donor 2 X 8 120 (15) X 8 130 (16)
Donor 3 130 2340 (18) 575 2070 (4)
Donor 4 X 8 125 (15) 125 815 (7)
a) Separated by anti-CD4/CD8 magnetic beads (see Sect. 4.3); 5 ± 105 lymphocytes/ml.
b) IFN- + was measured after 72 h of culture.
c) Numbers in parentheses indicate fold-increase over control.
ate the proliferation lesion. In addition, we compared
cytokine induction by C. pneumoniae with that of 10 ng/
ml Escherichia coli LPS. Induction of pro-inflammatory
cytokines by sonicated C. pneumoniae was lower when
compared with stimulation by endotoxin (TNF: 1140 ±
345 vs. 2005 ± 543 pg/ml, p X 0.05, IL-1 g : 247 ± 88 vs.
4431 ± 1238 pg/ml, p X 0.01; IL-6: 3154 ± 1453 vs.
16578 ± 8769 pg/ml, p X 0.01). However, induction of
pro-inflammatory cytokines by the acellular components
of C. pneumoniae was as strong as that induced by
infection of PBMC with corresponding numbers of live
chlamydial microorganisms (TNF: 970 ± 233 vs. 817 ±
338 pg/ml, p X 0.05; IL-1 g : 334 ± 171 vs. 405 ± 112 pg/
ml, p G 0.05).
In addition, C. pneumoniae strongly induced production
of the chemokines IL-8, MCP-1 and MIP-1 § in these
same cultures (Fig. 1 B). The induction of IL-8 by
C. pneumoniae was dose dependent (38134 ± 11543
pg/ml by 104 IFU/ml; 10112 ± 3438 pg/ml by 103 IFU/ml;
3567 ± 1987 pg/ml by 102 IFU/ml; p X 0.01 by Kruskall-
Wallis ANOVA).
As shown in Table 1, IFN- + was also induced by C. pneu-
moniae sonicates derived from 1 × 104 IFU/ml. Control
sonicates from uninfected cultures induced small but
measurable IFN- + in some donors. However, in PBMC
and purified lymphocyte cultures, the fold increase in
IFN- + production ranged from 4 to 18 using chlamydial
sonicates. The amounts of IFN- + induced in PBMC and
in purified lymphocyte cultures was modestly greater in
PBMC, suggesting that the presence of monocytes may
contribute to IFN- + production induced by chlamydial
products.
2.2 The role of endogenous cytokines in the
C. pneumoniae-induced cytokine production
Previous studies have shown that endogenous TNF and/
or IL-1 are important factors in the downstream synthe-
sis of other cytokines [26, 27]. To test whether this is also
the case in C. pneumoniae-stimulated cytokine produc-
tion, we stimulated cells with Chlamydia sonicates in the
presence of TNF-binding protein (TNFbp) or IL-1 recep-
tor antagonist (IL-1Ra), both at a final concentration of
10 ? g/ml.
As shown in Fig. 2 A, neutralization of endogenous TNF
by TNFbp resulted in a significant reduction in the pro-
duction of IL-8 (77 % reduction, p X 0.01), MCP-1 (44 %,
p X 0.05) and MIP-1 § (70 %, p X 0.01). Blockade of
IL-1R by IL-1Ra, and the subsequent neutralization of
endogenous IL-1 action, significantly inhibited produc-
tion of IL-8 (53 %, p X 0.05), but not of MCP-1 and MIP-
1 § (Fig. 2 B). In contrast, neither TNFbp (Fig. 3 A) nor
IL-1Ra (Fig. 3 B) reduced the production of IL-1 g , TNF or
IL-6. In this respect, it appears that stimulation of the syn-
thesis of TNF, IL-1 g and IL-6 by Chlamydia is indepen-
dent of each other. Using E. coli LPS in human PBMC,
IL-6 production is reduced by TNFbp or IL-1Ra [28].
To test whether stimulation of IFN- + synthesis by
C. pneumoniae sonicates is mediated by endogenous IL-
18 (IFN- + -inducing factor) [29], the cells were separately
co-incubated with either an IL-1 g converting enzyme
(ICE) inhibitor (final concentration 10 ? M) or IL-1Ra
(10 ? g/ml). The ICE inhibitor blocks the processing of
both pro-IL-18 and pro-IL-1 g , whereas IL-1Ra blocks the
action of the endogenously released IL-1( § and g ). The
addition of IL-1Ra had no effect on IFN- + production
(not shown). In contrast, inhibition of ICE significantly
reduced the stimulation of IFN- + /synthesis by sonicates
of C. pneumoniae by 54 % (771 ± 324 vs. 1683 ± 467 pg/
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Fig. 2. The effect of TNFbp and IL-1Ra on C. pneumoniae-
stimulated production of chemokines. PBMC were incu-
bated with C. pneumoniae sonicates in the absence (open
bars) or presence (hatched bars) of (A) 10 ? g/ml TNFbp or
(B) 10 ? g/ml IL-1Ra; n = 6 donors. *p X 0.01 and #p X 0.05
when compared with stimulation by Chlamydia sonicate
alone.
Fig. 3. Effect of TNFbp and IL-1Ra on C. pneumoniae stim-
ulation of IL-1 g , TNF and IL-6. PBMC were stimulated with
C. pneumoniae in the absence (open bars) or presence
(hatched bars) of TNFbp (A) or IL-1Ra (B); n = 6 donors.
Fig. 4. Effect of polymyxin B on C. pneumoniae stimulation
of TNF. Sonicated C. pneumoniae or E. coli LPS (10 ng/ml)
were preincubated for 2 h with 2 ? g/ml polymyxin B before
being added to PBMC. Open bars, untreated; hatched bars,
treated with polymyxin B; n = 4 donors. *p X 0.01 when
compared with the stimulus alone.
ml, p X 0.05). This inhibition suggests an important role
of endogenous IL-18 for stimulation of IFN- + by chla-
mydial acellular components.
2.3 LPS does not play a major role in the
stimulation of cytokine production by
sonicates of C. pneumoniae
C. pneumoniae is a gram-negative microorganism, and
the LPS component of gram-negative bacteria cell wall is
one of the most potent stimuli of cytokine production. To
test the hypothesis that chlamydial LPS may account for
the induction of cytokines, before being added to PBMC
sonicated C. pneumoniae was preincubated for 2 h at
37 °C with 2 ? g/ml polymyxin B, an antibiotic which
binds and neutralizes LPS derived from most gram-
negative bacteria. As shown in Fig. 4, polymyxin B inhib-
ited the TNF production induced by 10 ng/ml E. coli LPS
( G 95 % inhibition). However, preincubation with poly-
myxin B did not influence the C. pneumoniae-stimulated
TNF synthesis to further test the involvement of
chlamydial-derived LPS, the cytokine induction capacity
of heat-killed (30 min, 100 °C) Chlamydia-containing
supernatants was compared with that of sonicated Chla-
mydia. Sonicated Chlamydia supernatants induced
1821 ± 434 pg/ml TNF, whereas following heat treatment
this was reduced to 636 ± 302 pg/ml (65 % reduction,
p X 0.02). This suggests that a heat-labile epitope, rather
than the heat-resistant LPS, is largely responsible for
cytokine synthesis after stimulation of human PBMC
with C. pneumoniae.
2.4 The cellular source of cytokine production
To investigate which cell population in the PBMC is
responsible for the induction of cytokines after stimula-
tion with sonicates of C. pneumoniae, identical numbers
of PBMC and lymphocytes from the same volunteers
were stimulated with sonicated Chlamydia. TNF and IL-8
induced by stimulation with C. pneumoniae were almost
exclusively synthesized in unfractionated PBMC, but not
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Fig. 5. TNF and IL-8 in purified lymphocyte populations.
PBMC and lymphocytes from the same donors were incu-
bated with sonicated C. pneumoniae for 24 h. (A) TNF pro-
duction from PBMC (open bars) and lymphocytes (hatched
bars). (B) IL-8 production from PBMC (open bars) and lym-
phocytes (hatched bars); n = 4 donors. *p X 0.01 when com-
pared with production from PBMC.
in purified lymphocytes (Fig. 5). These results suggest
that the monocytes in PBMC are the source of TNF and
IL-8 when stimulated by Chlamydia sonicates. In con-
trast, IFN- + from purified lymphocytes and unfraction-
ated PBMC from the same donors was synthesized in
equal amounts (Table 1).
3 Discussion
The present study demonstrates that stimulation of
human PBMC with sonicates of C. pneumoniae induces
the production of the chemokines IL-8, MCP-1 and MIP-
1 § , as well as the pro-inflammatory cytokines TNF, IL-1 g
and IL-6. These sonicates preferentially stimulated IL-6
and IL-8 production, which may have specific pathologi-
cal implications. In addition, IFN- + production was also
demonstrated in both PBMC and purified lymphocytes
cultures. Whereas C. pneumoniae induced production of
TNF, IL-1 and IL-6 independent of each other, the pro-
duction of IL-8, MCP-1 and MIP-1 § is dependent on
endogenous TNF. In addition, the production of IL-8, but
not MCP-1 or MIP-1 § , is also partially dependent on
endogenous IL-1. These results are different from those
observed following stimulation of PBMC with E. coli LPS,
where MIP-1 § was suppressed by IL-1 blockade more
than 70 % [30].
The role of chronic low-grade infection of the arterial wall
with C. pneumoniae in the pathogenesis of atherosclero-
sis has been indirectly suggested by a series of epidemi-
ological and pathological studies reported during the last
decade (for review see [7]). The bacteria may either infect
an intact vessel wall, leading to inflammation and athero-
genesis, or infect an established atherosclerotic plaque,
leading to instability and rupture. There are several
potential mechanisms by which C. pneumoniae could
influence atherogenesis. Several studies have demon-
strated the expression of pro-inflammatory cytokines
such as TNF, IL-1 and IL-6 in atheromatous plaques [31,
32]. TNF and IL-1 increase the expression of endothelial
adhesion molecules [33], enhance the uptake of oxidized
low density lipoprotein (LDL) through increased expres-
sion of macrophage scavenger receptors [34], regulate
the plaque stability [35], and induce production of
endogenous growth factors which regulate cell prolifera-
tion in the arterial cell wall [36], each potentially impor-
tant mechanisms in the process of atherosclerosis.
Therefore, induction of these inflammatory mediators by
Chlamydia, as shown in the present report, may be of
central importance for the pro-atherogenic affect of
C. pneumoniae infection. Moreover, we have also shown
in the present study that heat-labile antigen-like prod-
ucts in sonicated/killed C. pneumoniae, and not only
infection of monocytes with live bacteria ([19, 20] and the
present study), are able to induce release of pro-
inflammatory cytokines. The acellular components of
C. pneumoniae are as potent as the live microorganisms
themselves in stimulating the production of cytokines.
This may be of particular importance, since dead Chla-
mydia present in the atheromatous lesion may be a
source of antigen which would activate cells in a para-
crine and autocrine manner, and recent data suggest
that at late stages only chlamydial antigens, and not live
bacteria, persist and maintain the chronic inflammation
[37]. A similar case has been made for reactive arthritis,
where disease progresses despite antibiotic therapy for
the C. trachomatis.
One of the important steps in the early phase of athero-
genesis is migration of monocytes and lymphocytes into
the arterial vessel wall. Leukocyte migration across the
endothelium is under control of chemokines, such as
IL-8, MCP-1 and MIP-1 § [38]. Such chemokines are pro-
duced after cholesterol loading of macrophages [39],
and have been detected in human atheromatous
plaques [32, 40]. A recent study has demonstrated that a
leukocyte homologue of the IL-8R mediates the accumu-
lation of macrophages in the atherosclerotic lesions of
LDL receptor-deficient mice [41], demonstrating the cen-
tral role of the chemokines in the development of athero-
sclerosis. In the present study we have demonstrated
that C. pneumoniae induces production of large amounts
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of IL-8, MCP-1 and MIP-1 § after stimulation of human
PBMC. Assuming that this takes place in the vessel wall,
the result could be accumulation of monocytes and lym-
phocytes in a developing plaque with subsequent pro-
gression of atherogenesis. The relevance of this issue
increases as it has been shown that the spread of chla-
mydial infection in the vessel wall is mediated through
infected monocytes [42]. The results of our study are
supported by the study of Molestina et al. [43] who
showed that a strain of C. pneumoniae isolated from
human atheromas induces production of MCP-1, IL-8
and soluble (s) ICAM-1 from human umbilical endothelial
cells and stimulates transendothelial migration of neutro-
phils and monocytes [23].
We tested the hypothesis that TNF and IL-1 are proximal
mediators of C. pneumoniae-stimulated cytokine pro-
duction, by blocking these cytokines with TNFbp or
IL-1Ra, and found that chlamydial stimulation of chemo-
kines is largely modulated by endogenous TNF. The pro-
duction of IL-8, but not MCP-1 and MIP-1 § , is also
dependent on endogenous IL-1, as also previously
shown for C. trachomatis and C. psitacci-stimulated pro-
duction of IL-8 [44]. This is not surprising, as TNF/IL-1-
driven induction of IL-8 has been reported for other stim-
uli as well [27, 45, 46]. Elucidation of the mechanism of
the cytokine cascade induced by C. pneumoniae may
prove particularly useful in finding therapeutic strategies
to counteract its deleterious effects.
Monocytes are the major source of TNF and IL-8 in the
present experiments, whereas lymphocytes respond
with significant production of IFN- + after stimulation with
C. pneumoniae. The lymphocyte populations, however,
contained 2–5 % contaminating monocytes and NK
cells. It was therefore considered that induction of IFN- +
in lymphocyte preparations is modulated through initial
induction of IL-12 and IL-18 from monocytes and/or NK
cells [29]. Indeed, inhibition of pro-IL-18 and pro-IL-1 g
processing by an ICE inhibitor reduced the stimulation of
IFN- + by C. pneumoniae by more than 50 %. As IL-1Ra
had no effect of IFN- + synthesis, this demonstrates that
endogenous IL-18 is involved in Chlamydia stimulation of
IFN- + . The remaining IFN- + synthesis is probably medi-
ated by endogenous IL-12. A possible correlation may
exist between the production of IFN- + and the state of
immunity to C. pneumoniae, and we are currently per-
forming a larger study investigating this aspect.
Despite the accumulating data suggesting induction of
cytokine production by C. pneumoniae and the potential
role of these molecules in the development of athero-
sclerosis, very little is known about the chlamydial anti-
gens responsible for cytokine stimulation. Since LPS
from the related species C. trachomatis has been shown
to induce cytokine production [47], one may expect that
C. pneumoniae LPS is also involved in the induction of
pro-inflammatory cytokines. However, the inability of
polymyxin B to inhibit the stimulation of cytokines by
C. pneumoniae argues against a major role of LPS in the
induction of cytokines by C. pneumoniae. Further, the
reduction of cytokine-inducing property following heat-
ing of the C. pneumoniae preparation suggests that a
heat-labile chlamydial component, and not the heat-
resistant LPS, is mainly responsible for cytokine stimula-
tion. Similar inhibition after heat inactivation was also
observed when endothelial cells were stimulated with
C. pneumoniae [43]. In contrast, the study of Ingalls et al.
[48] performed with LPS extracted from C. trachomatis
suggests that chlamydial endotoxin can stimulate cyto-
kine production [47]. Differences in structure between
LPS of various Chlamydia species may partly account for
this discrepancy. In addition, Ingalls et al. [48] have
shown that C. trachomatis LPS has a low biological
activity, and it should be noted that they isolated LPS
from 109 IFU/ml, which is five orders of magnitude higher
than our antigenic preparation. Of note, heat killing of
C. pneumoniae in our study did not lead to a complete
loss of cytokine induction, suggesting that chlamydial
LPS may play a limited role in the stimulation of cyto-
kines. Other indirect evidence suggests that LPS-like
products are not the major components responsible for
the cytokine-inducing property of the Chlamydial soni-
cates. For example, T cell production of IFN- + was simi-
lar in purified lymphocytes preparations and monocyte-
rich unfractionated PBMC. Taken together, the data sup-
port a non-LPS, cytokine-inducing product in the acellu-
lar Chlamydial sonicates. It has been recently reported
that chlamydial heat shock protein 60 is able to induce
production of TNF and matrix metalloproteinases by
macrophages [24, 25], whereas the MOMP of the related
species C. trachomatis is also able to stimulate produc-
tion of IL-1 [48], indicating these two chlamydial antigens
as possible candidates responsible for cytokine stimula-
tion.
4 Materials and methods
4.1 Reagents
E. coli LPS (serotype 055:B5) and polymyxin B were
obtained from Sigma Chemical Co. (St. Louis, MO). Recom-
binant human TNFbp was a kind gift of Dr. Carl Edwards
(Amgen, Boulder, CO). Recombinant human IL-1Ra was
kindly provided by Dr. Daniel Tracey (Upjohn, Kalamazoo,
MI). ICE inhibitor II (Ac-Tyr-Val-Ala-Asp-chloromethylketone)
was purchased from Bachem (Bubendorf, Switzerland).
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4.2 C. pneumoniae
C. pneumoniae TW-183 was grown in Hep2 cells, cultured in
MEM (Hepes buffered) containing 10 % FCS, 0.5 % (w/v)
glucose and 0.5 % (w/v) cycloheximide (Flow Laboratories,
Irvine, GB). After 48, 72 and 96 h, the supernatant containing
elementary bodies released from the cells was collected and
pooled. The cell debris was separated by low-speed centri-
fugation (10 min, 500 × g). The infectivity of the Chlamydia-
containing supernatants was further tested in Hep2 cells
and adjusted to 104 IFU/ml. As a control, supernatants from
cultures of uninfected Hep2 cells were collected and pre-
pared in a similar manner as described above. C. pneumo-
niae was killed either by sonication (10 min on ice) (Bran-
sonic 2200, Branson, Shelton, CT) or by heat (30 min,
100 °C). The same procedure was followed for the condi-
tioned medium obtained from uninfected Hep2 cells.
4.3 Isolation of human PBMC and lymphocytes
Venous blood was drawn from a cubital vein of healthy
volunteers into three 10-ml EDTA tubes (Monoject,
s-Hertogenbosch, The Netherlands). Isolation of PBMC was
performed as described elsewhere [49], with minor
modifications. The PBMC fraction was obtained by density
centrifugation of blood diluted 1:1 in pyrogen-free saline
over Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Swe-
den). PBMC were washed twice in saline and suspended in
the culture medium (RPMI 1640 DM) supplemented with
10 ? g/ml gentamicin, 10 mM L-glutamine and 10 mM pyru-
vate. The cells were counted in a Coulter counter (Coulter
Electronics, Mijdrecht, The Netherlands) and the number
was adjusted to 5 × 106 cells/ml.
In separate experiments, PBMC isolated from the Ficoll-
Paque gradients were incubated for 60 min with a 1:3
mixture of anti-CD4 and anti-CD8-bound magnetic
beads (Dynal, Oslo, Norway). The incubation was per-
formed at 4 °C with both gentle tilting and rotation. The
cells were isolated by magnet according to the manufac-
turer’s recommendations, and the supernatant was dis-
carded. The cells were washed three times in cold PBS.
The cells were detached from the magnetic beads by
incubation with DETACHaBEADs (10 ? l for 100 ? l cell
suspension) (Dynal) for 45 min at room temperature,
under gentle tilting and rotation. The released beads
were collected with the magnet, and the lymphocytes in
the supernatant were washed three times with cold PBS
to remove the magnetic beads. The lymphocyte popula-
tion obtained was G 95 % pure, as tested by flow cytom-
etry analysis (Becton Dickinson, Mountain View, CA). The
rest of the cells (2 to 5 %) were monocytes and NK cells.
4.4 Stimulation of cytokine production
PBMC (5 × 105 in 100 ? l) were added to round-bottom 96-
wells plates (Greiner, Alphen a/d Rijn, The Netherlands) fol-
lowed by 100 ? l conditioned medium from uninfected Hep2
cells, or sonicated or heat-killed C. pneumoniae. After 24 h
or 72 h incubation at 37 °C, the supernatants were collected
and stored at − 70 °C until assay.
4.5 Cytokine measurements
TNF- § and IL-1 g concentrations were determined by spe-
cific radioimmunoassays as described [50]. IL-6, IL-8 and
IFN- + were measured by commercial ELISA kits (Pelikine
Compact, CLB, Amsterdam, The Netherlands), according to
the instructions of the manufacturer. MCP-1 and MIP-1 §
determinations were performed using ELISA kits from R&D
(Quantikine, R&D Systems Europe, Abingdon, GB).
4.6 Statistical analyses
The differences between groups were analyzed by Mann-
Whitney U test, and where appropriate by Kruskal-Wallis
ANOVA test. The level of significance between groups was
set at p X 0.05. The data are given as means ± SEM.
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